Cleveland Clinic Names Stent Retriever Technology One of the Top Medical Innovations for 2016
October 28 2015 - 11:01AM
Medtronic
Pioneered the First Stent Retriever in 2007 with the
Introduction of the SolitaireTM Stent
Retriever Device
DUBLIN - October 28, 2015 -
The Cleveland Clinic has named stent retriever technology, which
includes Medtronic plc's (NYSE: MDT) SolitaireTM stent
retriever device, to a list of the top medical innovations for
2016. The top medical innovations list was revealed today at the
Cleveland Clinic's 2015 Medical Innovation Summit.
This news comes months after the American Heart
Association/American Stroke Association (AHA/ASA) published new
stroke treatment guidelines that recommend the use of stent
retriever technology in conjunction with the current standard of
care, IV-tPA, as a first-line treatment for eligible patients. The
guidelines were based on a panel of experts' analysis of the
results from five global clinical trials published in The New
England Journal of Medicine (NEJM) that found the addition of stent
retriever technology, a surgical procedure that manually removes
blood clots from the brain, to current medical therapy such as
IV-tPA, has a therapeutic benefit over medical therapy alone. These
trials, all of which studied the Solitaire device, showed that the
addition of stent retriever technology reduced disability, improved
neurological outcomes and increased the rate of return to
functional independence in patients suffering stroke.
"Since Medtronic's invention of the first stent
retriever in 2007, our commitment to fighting stroke and bringing
medical innovations to patients continues to grow," said Brett
Wall, president of the Neurovascular business, which is part of the
Restorative Therapies Group at Medtronic. "The five landmark global
clinical trials have proven the Solitaire device as a major
advancement in the treatment of stroke, reducing functional
disability in patients. Having this technology recognized by the
Cleveland Clinic's prestigious medical innovations list as well as
the new AHA/ASA guidelines has further validated our belief in
stent retrievers."
The Solitaire stent retriever uses a micro-sized
catheter to access arteries in the brain affected by stroke through
an incision in the leg. Once delivered, the device helps to
immediately restore blood flow and remove the blood clots causing
the stroke.
"The Cleveland Clinic's recognition of stent
retrievers as a top medical innovation further demonstrates that
this technology is a game-changer in stroke care," said Jeffrey L.
Saver, MD, FAHA, FAAN, FANA, professor of Neurology, Geffen School
of Medicine at the University of California, Los Angeles (UCLA) and
director, UCLA Comprehensive Stroke Center. "Stroke remains the
number five killer and the number one cause of severe disability in
the U.S. and we must ensure patients have access to these new
therapies that have ushered in a new era of stroke care."
Of the 695,000 acute ischemic stroke victims in
the U.S., about 240,000 are eligible for treatment with stent
retrievers. However, while these devices are available at more than
500 hospitals in the U.S., only about 13,000 procedures are
performed annually.
The Solitaire FR stent retriever device received
U.S. Food and Drug Administration 510(k) clearance in 2012 and
Solitaire FR received CE Mark approval in 2009.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 85,000 people worldwide, serving physicians,
hospitals and patients in more than 160 countries. The company is
focused on collaborating with stakeholders around the world to take
healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
Contacts:
David T. Young
Public Relations
+1-508-452-1644
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
HUG#1962125
Medtronic (NYSE:MDT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2023 to Mar 2024